OTC Pharmaceuticals in United Arab Emirates

Published: August 2013 · Publisher: MarketLine
OTC Pharmaceuticals in United Arab Emirates industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017).
Report Type Industry Profiles
Language English
Format Electronic (PDF)
Pages35
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-6955
Price € 259,00
Options
  • Description
  • Companies Mentioned
  • Table of Contents
  • Ask a Question
Introduction

OTC Pharmaceuticals in United Arab Emirates industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Arab Emirates otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2012 annual average exchange rates.

*The Emirati OTC pharmaceuticals market generated total revenues of $235.9m in 2012, representing a compound annual growth rate (CAGR) of 7.6% for the period spanning 2008-2012.

*The analgesics segment was the market's most lucrative in 2012, with total revenues of $56.7m, equivalent to 24% of the market's overall value.

*The performance of the market is forecast to accelerate, with an anticipated CAGR of 7.9% for the five-year period 2012-2017, which is expected to lead the market to a value of $345.2m by the end of 2017.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in United Arab Emirates

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in United Arab Emirates

Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the United Arab Emirates otc pharmaceuticals market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the United Arab Emirates economy

Key Questions Answered

What was the size of the United Arab Emirates otc pharmaceuticals market by value in 2012?

What will be the size of the United Arab Emirates otc pharmaceuticals market in 2017?

What factors are affecting the strength of competition in the United Arab Emirates otc pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitiors in United Arab Emirates's otc pharmaceuticals market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG and WellSpring Pharmaceuticals
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Category segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Category segmentation 9
Market share 10
Market distribution 11
Market Outlook 12
Market value forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
GlaxoSmithKline Plc 19
Johnson & Johnson 23
Novartis AG 26
WellSpring Pharmaceuticals 30
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34

LIST OF TABLES
Table 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2008–12 8
Table 2: United Arab Emirates OTC pharmaceuticals market category segmentation: $ million, 2012 9
Table 3: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2012 10
Table 4: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2012 11
Table 5: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2012–17 12
Table 6: GlaxoSmithKline Plc: key facts 19
Table 7: GlaxoSmithKline Plc: key financials ($) 20
Table 8: GlaxoSmithKline Plc: key financials (£) 21
Table 9: GlaxoSmithKline Plc: key financial ratios 21
Table 10: Johnson & Johnson: key facts 23
Table 11: Johnson & Johnson: key financials ($) 24
Table 12: Johnson & Johnson: key financial ratios 24
Table 13: Novartis AG: key facts 26
Table 14: Novartis AG: key financials ($) 27
Table 15: Novartis AG: key financial ratios 28
Table 16: WellSpring Pharmaceuticals : key facts 30
Table 17: United Arab Emirates size of population (million), 2008–12 31
Table 18: United Arab Emirates gdp (constant 2000 prices, $ billion), 2008–12 31
Table 19: United Arab Emirates gdp (current prices, $ billion), 2008–12 31
Table 20: United Arab Emirates inflation, 2008–12 32
Table 21: United Arab Emirates consumer price index (absolute), 2008–12 32
Table 22: United Arab Emirates exchange rate, 2008–12 32

LIST OF FIGURES
Figure 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2008–12 8
Figure 2: United Arab Emirates OTC pharmaceuticals market category segmentation: % share, by value, 2012 9
Figure 3: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2012 10
Figure 4: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2012 11
Figure 5: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2012–17 12
Figure 6: Forces driving competition in the OTC pharmaceuticals market in United Arab Emirates, 2012 13
Figure 7: Drivers of buyer power in the OTC pharmaceuticals market in United Arab Emirates, 2012 14
Figure 8: Drivers of supplier power in the OTC pharmaceuticals market in United Arab Emirates, 2012 15
Figure 9: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in United Arab Emirates, 2012 16
Figure 10: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in United Arab Emirates, 2012 17
Figure 11: Drivers of degree of rivalry in the OTC pharmaceuticals market in United Arab Emirates, 2012 18
Figure 12: GlaxoSmithKline Plc: revenues & profitability 21
Figure 13: GlaxoSmithKline Plc: assets & liabilities 22
Figure 14: Johnson & Johnson: revenues & profitability 24
Figure 15: Johnson & Johnson: assets & liabilities 25
Figure 16: Novartis AG: revenues & profitability 28
Figure 17: Novartis AG: assets & liabilities 29
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.